Ordinary thiamine , hydrochloride,
does it really help with Eight-week salbutamol-responsive digital reflective-index response?
research showsCurrent value: D, 28. The RI comparison in one crossover trial was nonsignificant, but clinically important benefit has not been excluded and equivalence is not established. [S01,S02]
ads claimNo separate advertising survey was conducted. These materials do not support claims of vascular cleansing, established FMD improvement, prevention of heart attack/stroke, or efficacy of all B1 products.
Four separate assessment dimensions
| Effect direction and size | Current value: D, 28. The RI comparison in one crossover trial was nonsignificant, but clinically important benefit has not been excluded and equivalence is not established. [S01,S02] |
|---|---|
| Evidence certainty | Confidence about clinically important benefit is low. This is a qualitative appraisal, not a certified GRADE assessment. |
| Applicability | Directly eligible for the selected eight-week RI response, not for FMD or long-term cardiovascular events. |
| Safety | Caution reflects unverified period-specific harms and longer-term high-risk-population safety, with separate official GI/hypersensitivity warnings. It is independent of efficacy grade D. |
B/S/R1/I1/E0/CX/B2. E0 gives D; zero strengths give the fixed score 28. R1 maps one trial family without turning an original pilot into a confirmatory trial. I1 for unverified funding does not assert demonstrated mixed funding.
Useful facts when choosing a product
- Actual report: oral thiamine hydrochloride 300 mg/day, eight-week periods and two-week washout. [S01]
- Registered product: Tyvera 100mg tablets with one listed active ingredient. Actual batch, excipients and free-thiamine equivalent unverified. [S03]
- The registered plan was once daily; actual administration schedule beyond the daily total is unverified. [S05,S01]
Chamgap Semantic Classification Code
Permanent code issued
S.thiamine.oral-thiamine-hydrochloride-300mg-day-8weeks-washout2weeks.adults-t2d-high-cv-risk-salbutamol-digital-reflective-index-end-8weeks.improve.placebo-crossover-background-careSubstances > Ordinary thiamine (vitamin B1) > Oral thiamine hydrochloride 300 mg/day for eight weeks with two-week washout > Salbutamol-responsive digital RI in high-CV-risk adults with T2D > Improve > Crossover placebo plus background care
The −1.5 contrast from RI 5.3±9.2 versus 6.8±6.9 (P=0.63) is descriptive in an unverified native unit; it is not converted to FMD, equivalence or cardiovascular-event prevention. The code identifies the intervention and claim; it never contains the evidence grade, score, or safety result.
Exact Claim Classification
These independent facets prevent evidence from different forms, routes, populations, effects, and comparators from being mixed.
| Intervention class | S · Supplement or nutraceutical |
|---|---|
| Canonical ingredient or intervention | Ordinary thiamine (vitamin B1), hydrochloride |
| Source or part used | Chemical nutrient; actual manufacturing origin and batch unverified; botanical part not applicable |
| Formulation or processing | One registered active ingredient, thiamine hydrochloride; registered tablet; actual product batch/excipients unverified |
| Route | oral |
| Dose | Reported 300 mg/day oral thiamine hydrochloride; free-thiamine equivalent and actual per-administration schedule unverified |
| Duration | 8 weeks per treatment period; 2-week washout between periods |
| Population | Adults with type 2 diabetes and high cardiovascular risk; actual mean age 61 years; baseline deficiency and numerical endothelial impairment unverified |
| Effect or condition | Improvement in salbutamol-responsive digital reflective-index response, not cardiovascular event prevention |
| Primary endpoint | Digital photoplethysmographic reflective-index response after inhaled salbutamol at end of an 8-week treatment period; not brachial FMD |
| Comparator | Placebo within the same crossover participants; background diabetes and cardiovascular medicines described, exact period balance unverified |
| Duplicate-detection key | S|ordinary-thiamine-hydrochloride|chemical-origin-unverified|single-active-registered-tablet-batch-unverified|oral|reported-300mg-day|8weeks-washout2weeks|adult-t2d-high-cv-risk-deficiency-unverified|salbutamol-digital-reflective-index-response|end-treatment-period8weeks|placebo-background-care|adjunctive-short-term-function |
What the research actually shows
After eight weeks of oral thiamine 300 mg/day versus placebo, reported RI values were 5.3 ± 9.2 versus 6.8 ± 6.9, P=0.63. Units, SD/SE and CI are unverified. [S02] No directly eligible FMD result was verified in this search, so the actual in-vivo salbutamol-responsive digital RI test was selected. This reflective index is neither FMD nor a cardiovascular event. [S01,S02] One crossover pilot family in adults with type 2 diabetes and high cardiovascular risk; 34 completers. Randomized and analyzed RI-pair counts remain separately unverified. Thesis, poster and registry are not counted as replication. [S01,S02,S03]
Why this is classified as D (28)
B/S/R1/I1/E0/CX/B2. E0 gives D; zero strengths give the fixed score 28. R1 maps one trial family without turning an original pilot into a confirmatory trial. I1 for unverified funding does not assert demonstrated mixed funding.
Counterpoint. Registered primary endpoint: VCAM-1. This page does not promote the RI functional endpoint to registered primary or claim a successful positive secondary outcome. [S03,S02]
Rejudgment record. Original nonsignificant RI result and native derivation agree; not independent external review — Unmodified rubric/calculator; zero-strength D anchor
| Endpoint | S | Surrogate marker - laboratory or imaging measures Case application: S: an in-vivo vascular-function surrogate after pharmacological challenge, not a hard event or patient symptom endpoint. |
| Replication | R1 | Single confirmatory trial Case application: R1 maps one directly eligible controlled family. Original sources call it pilot/exploratory; the rubric label does not make this trial confirmatory. Thesis, poster and registry are not replication. |
| Independence | I1 | Mixed funding sources Case application: Funding and trial-specific conflicts were not verified; the rubric explicitly uses I1 for this unresolved state. This does not assert that mixed funding was demonstrated. |
| Effect size | E0 | Null Case application: E0 follows the reported RI comparison P=0.63. This denotes the rubric nonsignificant-result pathway, not a proven zero effect or equivalence. |
| Precision | CX | No pooled confidence interval could be confirmed Case application: CX: no verified CI or MCID; meaningful benefit exclusion and the magnitude of residual benefit remain unresolved. |
Review performed and remaining limitations
RI units, variance type, challenge timing/sign convention, operator blinding, baseline values, paired analyzed counts, sequence/period/carryover terms, exact adjusted estimate, CI/MCID, actual batch and meal timing, individual adherence, period medication balance, baseline deficiency, funding/conflicts and arm-level safety remain unverified. Full thesis and end-of-study attachment were inaccessible. Search was bounded, not exhaustive.
Preliminary RoB 2-informed review — not a complete formal assessment
| Randomization | Randomized/double-blind reported; sequence generation and concealment details unverified. |
|---|---|
| Deviations from assigned interventions | Biochemical exposure increase verified; individual adherence and period-specific medication changes unverified. |
| Missing outcome data | 34 completers verified; randomized count, analyzed pairs and missing-data handling unverified. Complete-case analysis is not asserted as fact. |
| Outcome measurement | Digital RI challenge response. Units, SD/SE, challenge timing, operator blinding and sign convention unverified. |
| Selection of the reported result | Registered primary is VCAM-1. RI hierarchy, SAP and multiplicity are unverified; selective reporting is not declared proven. |
Reasons for the certainty judgment — not formal GRADE
| Risk of bias | concerns and incomplete verification; supplied rubric B2 for small/short chronic trial |
|---|---|
| Inconsistency | not estimable from a single directly eligible family |
| Indirectness | restricted to high-risk T2D and RI surrogate; baseline deficiency unknown |
| Imprecision | CI and MCID unverified; no equivalence or exclusion claim |
| Publication bias | cannot assess reliably from one family; not ruled out |
Search scope and limitations. 42 general-web queries and three failed native-search attempts; no exhaustive-search assurance
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Page et al. 2013 oral-thiamine crossover pilot in high-CV-risk adults with T2D | Randomized double-blind crossover pilot; two eight-week periods separated by two weeks; 34 completers | 34 unique completers; randomized count, sequence denominators and analyzed RI pairs unverified | Trial-specific funding, product provision and conflicts unverified; noncommercial sponsorship is not treated as proof of independent funding | Digital photoplethysmographic reflective-index response after inhaled salbutamol at eight weeks; not FMD and distinct from registered primary VCAM-1 | Thiamine 5.3±9.2 versus placebo 6.8±6.9, P=0.63; difference −1.5. Unit, SD/SE, CI and MCID unverified | Only direct family for the locked endpoint; nonsignificance is not extended to no effect, equivalence, FMD or cardiovascular-event prevention |
Receipt — 9 References
Evidence access cutoff: 2026-09-16. Each citation states its actual access level (full-text transcription, abstract, index, or other) and remaining limitations. Bibliographic checking does not certify the study results or treatment efficacy.
Technical integration by: Codex · Evidence date: 2026-09-16 · Corrections: none
Cite this verdict
[Chamgap] Oral thiamine hydrochloride × eight-week reflective-index response in high-risk adults with type 2 diabetes — Evidence Grade D·28. 9 cited sources checked. Source: https://chamgap.com/en/verdicts/heart/oral-thiamine-t2d-salbutamol-digital-ri-8-weeks/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.